XML 75 R61.htm IDEA: XBRL DOCUMENT
v3.10.0.1

License Agreements - Syros (Details) $ / shares in Units, $ in Thousands, shares in Millions | 1 Months Ended | 12 Months Ended |
--- | --- | --- | ---
Jan. 31, 2018 USD ($) item $ / shares shares | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($) | Jan. 08, 2018 $ / shares
License agreements |  |  |  |  |
Long term investment |  | $ 99,199 | $ 134,356 |  |
Research and development expense |  | 1,197,957 | 1,326,134 | $ 581,861 |
Unrealized gain (loss) on long term investments |  | (44,093) | $ (24,275) | $ (3,261) |
Syros Pharmaceuticals, Inc. |  |  |  |  |
License agreements |  |  |  |  |
Number of program targets | item | 7 |  |  |  |
Upfront payment under license agreement | $ 10,000 |  |  |  |
Fair value of shares on the issuance date |  | $ 5,200 |  |  |
Ownership percentage (as a percent) |  | 3.00% |  |  |
Unrealized gain (loss) on long term investments |  | $ (3,700) |  |  |
Syros Pharmaceuticals, Inc. | Stock purchase agreement |  |  |  |  |
License agreements |  |  |  |  |
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares | 0.8 |  |  |  |
Purchase price of common stock | $ 10,000 |  |  |  |
Per share price | $ / shares | $ 12.61 |  |  |  | $ 9.77
Lock-up period | 12 months |  |  |  |
Discount for lack of marketability | $ 100 |  |  |  |
Fair value of shares on the issuance date | 7,600 |  |  |  |
Long term investment | 7,600 |  |  |  |
Research and development expense | $ 2,400 |  |  |  |
Syros Pharmaceuticals, Inc. | Amended stock purchase agreement |  |  |  |  |
License agreements |  |  |  |  |
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares | 0.1 |  |  |  |
Purchase price of common stock | $ 1,400 |  |  |  |
Per share price | $ / shares | $ 9.55 |  |  |  |
Syros Pharmaceuticals, Inc. | Maximum |  |  |  |  |
License agreements |  |  |  |  |
Target selection and option exercise fee payment | $ 54,000 |  |  |  |
Syros Pharmaceuticals, Inc. | Development and Regulatory Milestones | Maximum |  |  |  |  |
License agreements |  |  |  |  |
Additional milestone payments under the license agreement | 50,000 |  |  |  |
Syros Pharmaceuticals, Inc. | Commercialization Milestones | Maximum |  |  |  |  |
License agreements |  |  |  |  |
Additional milestone payments under the license agreement | $ 65,000 |  |  |  |

X
- Definition Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References No definition available. + Details
Name: | incy_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Adjustment to the amount of discount used to measure fair value for lack of ability to convert business interests into cash quickly.. + References No definition available. + Details
Name: | incy_FairValueInputsAmountOfDiscountForLackOfMarketability
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the additional milestone payments to be made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementAdditionalMilestonePayments
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the target selection and option exercise fee payments to be made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the amount of the upfront payment made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementUpfrontPaymentAmountPaid
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the number of program targets identified. + References No definition available. + Details
Name: | incy_NumberOfProgramTargets
Namespace Prefix: | incy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the purchase of common stock under Stock Purchase Agreement. + References No definition available. + Details
Name: | incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares
Namespace Prefix: | incy_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period of time that the company will not sell or otherwise transfer any of the equity method shares. + References No definition available. + Details
Name: | incy_StockPurchaseAgreementLockUpPeriod
Namespace Prefix: | incy_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value of the entity's equity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_EquityFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This element represents the aggregate cost of investments accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestmentAggregateCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_LongTermInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_StockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AmendedStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |